Abstract

Chairpersons : Dr Lalit Verma, Dr Dinesh Talwar

Convenors : Dr Shrinivas Joshi, Dr Mallika Goyal

Co-Convenors : Dr Avnindra Gupta, Dr Atul Dhawan

Moderator : Dr Dhananjay Shukla

Anti VEGF’s agents are a hot topic. Various trials are available to justify their usage in Ophthalmology. Entrance of Biosimilars have made treatment competitive. Newer Anti VEGF’s give us hope to reduce treatment burden. Financial aspects have increased the abuse. Let us try to rationalise their usage for the maximal benefit for our patients.

1. Angiogenesis – An overview ( 10’ ) : Dr Santosh Gopi Krishna

2. Use of Anti VEGF`s in Retinal Diseases ( 15’ ) : Dr Anand Rajendran

3. Biosimilars in Retinal Practice ( 10’ ) : Dr Ashish Sharma

4. Newer Anti VEGF`s ( 10’ ) : Dr Debdulal Chakraborty

5. Pharmacoeconomics of Anti VEGF’s ( 10‘ ) : Dr Pradeep kumar

6. Markers & Road ahead ( Can we titrate / Prognosticate ? ) ( 10’ ) : Dr Thirumalesh M.B

7. Abuse of Anti VEGF’s ( 10’ ) : Dr Dinesh Talwar

Concluding Remarks

1	Angiogenesis – An overview ( 10’ )	Dr Santosh Gopi Krishna	watch video
2	Use of Anti VEGF`s in Retinal Diseases ( 15’ )	Dr Anand Rajendran	watch video
3	Biosimilars in Retinal Practice ( 10’ )	Dr Ashish Sharma	watch video
4	Newer Anti VEGF`s ( 10’ )	Dr Debdulal Chakraborty	watch video
5	Pharmacoeconomics of Anti VEGF’s ( 10‘ )	Dr Pradeep kumar	watch video
6	Markers & Road ahead ( Can we titrate / Prognosticate ? ) ( 10’ )	Dr Thirumalesh M.B	watch video
7	Abuse of Anti VEGF’s ( 10’ )	Dr Dinesh Talwar	No Video